ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 1, 2005, Pages

  Van Cutsem, E J D ^a,d   Oliveira, J ^b,d   Kataja, V V ^c,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d ESMO Guidelines Task Force   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; ARTICLE; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; DRUG RESPONSE; EUROPEAN UNION; FOLLOW UP; HUMAN; LIVER METASTASIS; LIVER SURGERY; LUNG METASTASIS; LUNG SURGERY; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE; NEOPLASM STAGING; RISK ASSESSMENT;

EID: 21044454199     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi803     Document Type: Article

References (9)

1. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
2. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
3. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
4. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
5. Goldberg RM, Sargent DJ et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
6. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOL-FOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
7. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised phase III trials. Brit J Cancer 2004; 90: 1190-1197.
8. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
9. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345.